HERMIONE: A randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

  1. Miller, K.
  2. Cortes, J.
  3. Hurvitz, S.A.
  4. Krop, I.E.
  5. Tripathy, D.
  6. Verma, S.
  7. Riahi, K.
  8. Reynolds, J.G.
  9. Wickham, T.J.
  10. Molnar, I.
  11. Yardley, D.A.
Revista:
BMC Cancer

ISSN: 1471-2407

Año de publicación: 2016

Volumen: 16

Número: 1

Tipo: Artículo

DOI: 10.1186/S12885-016-2385-Z GOOGLE SCHOLAR lock_openAcceso abierto editor